Malignant Solid Tumor Clinical Trials

8 recruiting

Malignant Solid Tumor Trials at a Glance

46 actively recruiting trials for malignant solid tumor are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 30 trials, with the heaviest enrollment activity in Shanghai, Houston, and Nashville. Lead sponsors running malignant solid tumor studies include Minghui Pharmaceutical (Hangzhou) Ltd, Shanghai Virogin Biotech Co., Ltd., and Suzhou Suncadia Biopharmaceuticals Co., Ltd..

Browse malignant solid tumor trials by phase

Treatments under study

About Malignant Solid Tumor Clinical Trials

Looking for clinical trials for Malignant Solid Tumor? There are currently 8 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Malignant Solid Tumor trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Malignant Solid Tumor clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 46 trials

Recruiting

Natural History and Biospecimen Acquisition for Children and Adults With Rare Solid Tumors

Solid TumorPediatric Solid TumorMalignant Solid Tumors+2 more
National Cancer Institute (NCI)10,000 enrolled3 locationsNCT03739827
Recruiting
Phase 1Phase 2

A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors

Locally Advanced or Metastatic Malignant Solid Tumors
Astellas Pharma Global Development, Inc.428 enrolled7 locationsNCT07287995
Recruiting
Phase 2

A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.

Malignant Solid Tumor
Centre Leon Berard455 enrolled10 locationsNCT04116541
Recruiting
Phase 1Phase 2

A Study of TAK-505 in Adults With Solid Tumors

Malignant Solid Tumors
Takeda151 enrolled15 locationsNCT07436728
Recruiting
Phase 1Phase 2

A Study of MHB048C in Patients With Advanced Solid Tumors

Advanced Malignant Solid TumormCRPC (Metastatic Castration-resistant Prostate Cancer)
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192120
Recruiting
Phase 1Phase 2

A Study of MHB009C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07326488
Recruiting
Phase 1Phase 2

A Study of MHB042C in Patients With Advanced Solid Tumors

Advanced Malignant Solid Tumor
Minghui Pharmaceutical (Hangzhou) Ltd200 enrolled1 locationNCT07192107
Recruiting
Phase 1

Clinical Trial of IL - 22BP Safety, Tolerability, and Antitumor Activity in Refractory Solid Tumors.

Refractory Malignant Solid TumorsmRNA VaccineInterleukin
West China Hospital6 enrolled2 locationsNCT07040943
Recruiting
Phase 1

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2062 in Patients With Solid Tumors

Advanced Malignant Solid Tumor
Shanghai Virogin Biotech Co., Ltd.30 enrolled1 locationNCT07262164
Recruiting
Not Applicable

Anti-HER2 CAR-T Cell Injection in Patients With HER2-positive Advanced Malignant Solid Tumors

HER2-positive Advanced Malignant Solid Tumors
UTC Therapeutics Inc.30 enrolled1 locationNCT06658951
Recruiting
Phase 1Phase 2

Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients

Hepatocellular CarcinomaRefractory Solid TumorPediatric Solid Tumor+3 more
St. Jude Children's Research Hospital64 enrolled2 locationsNCT05468359
Recruiting
Phase 1

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Advanced Solid TumorMetastatic Solid TumorSolid Tumor+4 more
Ankyra Therapeutics, Inc97 enrolled5 locationsNCT06171750
Recruiting
Phase 2

A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.120 enrolled1 locationNCT07028281
Recruiting
Phase 1

A First in Human Study of PLT012 in Participants With Solid Tumor Cancers

Solid Tumor CancerAdvanced Malignant Solid Tumor
Pilatus Biosciences Inc36 enrolled2 locationsNCT07337525
Recruiting
Phase 2

Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Malignant Solid Tumors
M.D. Anderson Cancer Center40 enrolled1 locationNCT06629584
Recruiting
Phase 1Phase 2

An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors

Advanced Malignant Solid Tumor
Repertoire Immune Medicines150 enrolled1 locationNCT07293754
Recruiting
Phase 1

Study of ISM6331 in Participants With Advanced/Metastatic Malignant Mesothelioma or Other Solid Tumors

Advanced Solid TumorMalignant MesotheliomaMetastatic Malignant Solid Tumor
InSilico Medicine Hong Kong Limited100 enrolled10 locationsNCT06566079
Recruiting
Phase 1

A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function

Advanced Malignant Solid TumorHepatic Impairment
Epizyme, Inc.24 enrolled18 locationsNCT04241835
Recruiting
Phase 1Phase 2

Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors

Advanced Solid TumorMalignant Solid Tumor
Daiichi Sankyo250 enrolled25 locationsNCT04145622
Recruiting
Phase 2

A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors

Malignant Solid Tumors
Shanghai Hengrui Pharmaceutical Co., Ltd.400 enrolled2 locationsNCT07268040